Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the safety, tolerability, and pharmacokinetics of E6742 in systemic lupus erythematosus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• E6742

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Lupus Erythematosus, Systemic | Phase 1, Phase 2 | Status: COMPLETED